MedTrace Logo

Blocking Mifepristone Action With Progesterone

NCT03774745 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-01-22

Study results available
· View outcomes & findings →

Summary

Double-blind randomized trial to evaluate the potential impact of progesterone treatment on early pregnancies exposed to mifepristone.

Conditions

  • Pregnancy, Unwanted

Interventions

DRUG

Mifepristone 200 MG

All subjects receive mifepristone tablet on treatment day 1.

DRUG

micronized Progesterone

Subjects randomized to progesterone receive treatment starting day 2.

DRUG

Placebo oral capsule

Subjects randomized to placebo receive treatment starting day 2.

Sponsors & Collaborators

Principal Investigators

  • Mitchell D Creinin, MD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-11
Primary Completion
2019-07-29
Completion
2019-08-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03774745 on ClinicalTrials.gov